SCHEMBL1237271

SCHEMBL1237271

Cc1nc(N)sc1-c1csc(S(=O)(=O)N2CCC(O)CC2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.39
LMNA P02545 5/20 0.39
ALDH1A1 P00352 5/20 0.39
HTT P42858 3/20 0.39
KDM4E B2RXH2 2/20 0.39
PIK3CA P42336 1/20 0.37
PIK3C3 Q8NEB9 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.36
GAA P10253 3/20 0.36
RAB9A P51151 2/20 0.36
USP2 O75604 2/20 0.36
HSD17B10 Q99714 2/20 0.36
NR2F2 P24468 1/20 0.36
TSHR P16473 1/20 0.36
MCOLN3 Q8TDD5 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CDK5 Q00535 1/20 0.34
CDK5R1 Q15078 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1236877 0.99 MAPT (0.38) MAPTLMNAALDH1A1HTTKDM4E
SCHEMBL1237672 0.85 KMT2A (0.41) MAPTLMNAALDH1A1HTTKDM4E
SCHEMBL1236720 0.83 PIK3CG (0.47) PIK3CAPIK3C3PIK3C2G
SCHEMBL1237551 0.77 PIK3CG (0.46) PIK3CAPIK3C3PIK3C2G
SCHEMBL1237555 0.73 PIK3CG (0.46) PIK3CAPIK3C3PIK3C2G
SCHEMBL1236616 0.72 PIK3CG (0.45) PIK3CAPIK3C3PIK3C2G
SCHEMBL1235188 0.72 PIK3CG (0.51) LMNAHTTPIK3CAPIK3C3USP2
SCHEMBL799259 0.71 PI4KB (0.39) MAPTLMNAALDH1A1HTTKDM4E
SCHEMBL1236893 0.71 PIK3CG (0.53) PIK3CAPIK3C3
SCHEMBL1614199 0.71 PIK3CG (0.43) PIK3CAPIK3C3PIK3C2G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399497-B2 Thiazole derivatives and use thereof MERCK SERONO SA (CH) 2013-03-19 US claimed
EP-1885716-B1 THIAZOLE DERIVATIVES AND USE THEREOF MERCK SERONO SA (CH) 2012-11-07 EP claimed
US-20110086843-A1 Thiazole Derivatives and Use Thereof MERCK SERONO SA (CH) 2011-04-14 US claimed
US-7879888-B2 N-(4-methyl-5-{5-[(prop-2-yn-1-ylamino)sulfonyl]-2-thienyl}-1,3-thiazol-2-yl)acetamide; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection MERCK SERONO SA (CH) 2011-02-01 US claimed
US-20080221180-A1 Thiazole Derivatives and Use Thereof LABORATORIES SERONO SA (CH) 2008-09-11 US claimed
EP-1885716-A1 THIAZOLE DERIVATIVES AND USE THEREOF Laboratoires Serono SA (CH) 2008-02-13 EP claimed
WO-2006125803-A1 THIAZOLE DERIVATIVES AND USE THEREOF LABORATOIRES SERONO S.A. (CH) 2006-11-30 WO claimed
US-8399497-B2 Thiazole derivatives and use thereof MERCK SERONO SA (CH) 2013-03-19 US disclosed
US-8399497-B2 Thiazole derivatives and use thereof MERCK SERONO SA (CH) 2013-03-19 US disclosed
US-8399497-B2 Thiazole derivatives and use thereof MERCK SERONO SA (CH) 2013-03-19 US disclosed
EP-1885716-B1 THIAZOLE DERIVATIVES AND USE THEREOF MERCK SERONO SA (CH) 2012-11-07 EP disclosed
EP-1885716-B1 THIAZOLE DERIVATIVES AND USE THEREOF MERCK SERONO SA (CH) 2012-11-07 EP disclosed
US-20110086843-A1 Thiazole Derivatives and Use Thereof MERCK SERONO SA (CH) 2011-04-14 US disclosed
US-20110086843-A1 Thiazole Derivatives and Use Thereof MERCK SERONO SA (CH) 2011-04-14 US disclosed
US-7879888-B2 N-(4-methyl-5-{5-[(prop-2-yn-1-ylamino)sulfonyl]-2-thienyl}-1,3-thiazol-2-yl)acetamide; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection MERCK SERONO SA (CH) 2011-02-01 US disclosed
US-7879888-B2 N-(4-methyl-5-{5-[(prop-2-yn-1-ylamino)sulfonyl]-2-thienyl}-1,3-thiazol-2-yl)acetamide; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection MERCK SERONO SA (CH) 2011-02-01 US disclosed
US-7879888-B2 N-(4-methyl-5-{5-[(prop-2-yn-1-ylamino)sulfonyl]-2-thienyl}-1,3-thiazol-2-yl)acetamide; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection MERCK SERONO SA (CH) 2011-02-01 US disclosed
US-20080221180-A1 Thiazole Derivatives and Use Thereof LABORATORIES SERONO SA (CH) 2008-09-11 US disclosed
US-20080221180-A1 Thiazole Derivatives and Use Thereof LABORATORIES SERONO SA (CH) 2008-09-11 US disclosed
US-20080221180-A1 Thiazole Derivatives and Use Thereof LABORATORIES SERONO SA (CH) 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221180-A1 Thiazole Derivatives and Use Thereof PDGFRB, PDGFRA, TEC MAPT 1418/4885LMNA 4765/4885ALDH1A1 174/4885
US-20110086843-A1 Thiazole Derivatives and Use Thereof PDGFRB, PDGFRA, TEC MAPT 1418/4885LMNA 4765/4885ALDH1A1 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.